Dr. Nilanjan Ghosh
Claim this profileLevine Cancer Institute
Studies Lymphoma
Studies B-Cell Lymphoma
9 reported clinical trials
13 drugs studied
Area of expertise
1Lymphoma
CCND1 positive
t(11;14) positive
Stage II
2B-Cell Lymphoma
CCND1 positive
t(11;14) positive
MYC positive
Affiliated Hospitals
Clinical Trials Nilanjan Ghosh is currently running
Rituximab vs Mosunetuzumab
for Follicular Lymphoma
This phase III trial compares the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. It is not yet known if giving rituximab or mosunetuzumab works better in treating patients with follicular lymphoma with a low tumor burden.
Recruiting2 awards Phase 313 criteria
Acalabrutinib
for CNS Lymphoma
The purpose of this study is to test whether giving acalabrutinib is safe and effective in controlling relapsed central nervous system (CNS) lymphoma. Currently, there are no FDA-approved treatments for relapsed CNS lymphoma. Although acalabrutinib has not been approved for the treatment of CNS lymphoma, it was approved for the treatment of another type of lymphoma (mantle cell), by the Food and Drug Administration (FDA). Acalabrutinib acts similar to another cancer drug called ibrutinib. lbrutinib was tested in several research trials for the management of CNS lymphomas, and the results were promising. Acalabrutinib and ibrutinib attack a similar target found in CNS lymphoma. Acalabrutinib may do a better job in attacking this target than ibrutinib. The study doctors will be looking to see if acalabrutinib can shrink cancer cells. The participants will be given acalabrutinib and isavuconazole, because isavuconazole helps in preventing fungal infections that may occur during acalabrutinib treatment.
Recruiting1 award Phase 2
More about Nilanjan Ghosh
Clinical Trial Related1 year of experience running clinical trials · Led 9 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Nilanjan Ghosh has experience with
- Rituximab
- Mosunetuzumab
- Acalabrutinib
- Isavuconazole
- CC-95251
- Cetuximab
Breakdown of trials Nilanjan Ghosh has run
Lymphoma
B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Follicular Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Nilanjan Ghosh specialize in?
Nilanjan Ghosh focuses on Lymphoma and B-Cell Lymphoma. In particular, much of their work with Lymphoma has involved CCND1 positive patients, or patients who are t(11;14) positive.
Is Nilanjan Ghosh currently recruiting for clinical trials?
Yes, Nilanjan Ghosh is currently recruiting for 5 clinical trials in Charlotte North Carolina. If you're interested in participating, you should apply.
Are there any treatments that Nilanjan Ghosh has studied deeply?
Yes, Nilanjan Ghosh has studied treatments such as Rituximab, Mosunetuzumab, Acalabrutinib.
What is the best way to schedule an appointment with Nilanjan Ghosh?
Apply for one of the trials that Nilanjan Ghosh is conducting.
What is the office address of Nilanjan Ghosh?
The office of Nilanjan Ghosh is located at: Levine Cancer Institute, Charlotte, North Carolina 28204 United States. This is the address for their practice at the Levine Cancer Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.